Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.

Yumiko OtaDaisuke TakahariTakeshi SuzukiHiroki OsumiIzuma NakayamaAkira OkiTakeru WakatsukiTakashi IchimuraMariko OguraEiji ShinozakiMitsukuni SuenagaKeisho ChinKensei Yamaguchi

Published in: Cancer chemotherapy and pharmacology (2020)

Nivolumab monotherapy was efficacious in gastric cancer patients. NLR changes during such therapy may be predictive of outcomes.

Keyphrases

combination therapy
open label
clinical trial
stem cells
randomized controlled trial
mesenchymal stem cells
metabolic syndrome
adipose tissue
skeletal muscle
glycemic control
replacement therapy
smoking cessation